(2022). EPH21 Real-world evidence of adverse kidney outcomes for intravitreal use of vascular endothelial growth factor (VEGF) inhibitors among patients with diabetic retinopathy.
Chicago Style (17th ed.) CitationEPH21 Real-world Evidence of Adverse Kidney Outcomes for Intravitreal Use of Vascular Endothelial Growth Factor (VEGF) Inhibitors Among Patients with Diabetic Retinopathy. 2022.
MLA (8th ed.) CitationEPH21 Real-world Evidence of Adverse Kidney Outcomes for Intravitreal Use of Vascular Endothelial Growth Factor (VEGF) Inhibitors Among Patients with Diabetic Retinopathy. 2022.
Warning: These citations may not always be 100% accurate.